Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
ESMO GI 2025
Top resúmenes y presentaciones
Event-free survival (EFS) and patient-reported outcomes
(PROs) in MATTERHORN: a randomised, Phase 3 study of
durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin
and docetaxel (FLOT)
LBA4
Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO)
+ CT in patients (pts) with locally advanced (LA)
esophageal squamous cell carcinoma (ESCC):
RATIONALE-306 subgroup analysis
389MO
Preliminary Safety and Efficacy of Givastomig, a Novel
Claudin 18.2/4-1BB Bispecific Antibody, in Combination with
Nivolumab and mFOLFOX in Metastatic Gastroesophageal
Carcinoma (mGEC)
388MO
ESMO GI 2025
ESOFAGOGÁSTRICOS
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Definitive Chemoradiotherapy for Adenocarcinoma of the
Esophagus: a Dutch Population-Based Cohort
390MO
Phase III randomized IRIGA trial of FOLFIRINOX versus
mFOLFOX6 as first-line treatment for patients with
HER2-negative gastric and gastroesophageal
adenocarcinoma
391MO
Health-related quality of life with 1L nivolumab plus
ipilimumab vs lenvatinib or sorafenib in patients with
unresectable hepatocellular carcinoma: CheckMate 9DW
148O
PANOVA-3: Pain and quality of life (QoL) outcomes with
Tumor Treating Fields (TTFields) therapy in patients with
locally advanced pancreatic adenocarcinoma (LAPC)
LBA3
TALENTACE: A phase III, open-label, randomized study of
on-demand transarterial chemoembolization (TACE)
combined with atezolizumab + bevacizumab (Atezo+Bev) or
on-demand TACE alone in patients with systemically
untreated, intermediate-to-high burden unresectable
hepatocellular carcinoma (uHCC)
LBA2
ESMO GI 2025
HEPATOBILIOPANCREÁTICO
Tu canal independiente de oncología en espa-
ñol
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
AGITG ASCEND study: Randomised, double-blind phase II
study of certepetide or placebo added to gemcitabine plus
nab-paclitaxel in patients with untreated metastatic
pancreatic ductal adenocarcinoma—Cohort B progression
free survival results
260MO
BXCL701 plus pembrolizumab in second-line advanced
pancreatic ductal adenocarcinoma
259MO
Preliminary efficacy outcomes of ivosidenib in patients
with IDH1 mutated cholangiocarcinoma (mIDH1 CCA):
initial results from the phase 3b ProvIDHe study.
262MO
Safety results from the Phase 3b SIERRA study of
durvalumab and tremelimumab as first-line treatment
for hepatocellular carcinoma participants with a poor
prognosis.
150MO
ESMO GI 2025
HEPATOBILIOPANCREÁTICO
Tu canal independiente de oncología en espa-
ñol
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
A Phase II Study of Olaparib in patients with Advanced
Biliary Tract Cancer with aberrant homologous recombinant
repair mutations.
261MO
Antitumour activity and safety of first-line zanidatamab +
cisplatin-gemcitabine in patients with HER2-expressing
biliary tract cancer (BTC)
319P
Early safety and efficacy from the phase IIIb
TOURMALINE study of durvalumab (D) in combination
with gemcitabine (G)-based chemotherapy in advanced
biliary tract cancer (aBTC)
323P
ADJUBIL: A phase II study of durvalumab and
tremelimumab with or without capecitabine in ADJUvant
BILiary tract cancer: The IKF/AIO-ADJUBIL trial
357P
Rechallenge with amivantamab, an EGFR-MET bispecific
antibody, after disease progression on prior EGFR
inhibitor in left-sided RAS/BRAF wild-type metastatic
colorectal cancer: Updated results from OrigAMI-1
6MO
Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO
monotherapy for microsatellite instability-high/mismatch
repair-deficient (MSI-H/dMMR) metastatic colorectal
cancer (mCRC): Health-related quality of life (HRQoL)
analyses from CheckMate 8HW
1O
Dynamic circulating tumor DNA methylation monitoring
guiding postoperative surveillance in non-metastatic
colorectal cancer: Interim analysis of FIND trial
LBA1
ESMO GI 2025
COLORRECTAL
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Clinical outcomes of modified (m)-FOLFOXIRI plus cetuximab
versus bevacizumab by metastasis status in RAS/BRAF
wild-type and left-sided metastatic colorectal cancer: The
DEEPER trial (JACCRO CC-13)
35P
Efficacy and safety of fruquintinib vs placebo by metastatic
site in metastatic colorectal cancer: A FRESCO-2 subgroup
analysis
37P
Liquid biopsy-guided selection for anti-EGFR
re-treatment in RAS/BRAF wild-type (wt)
chemorefractory metastatic colorectal cancer patients
(mCRC pts): Results from the phase II randomized
PARERE trial
4O
Clinical utility of including circulating tumor DNA (ctDNA)
monitoring in standard of care (SoC) colorectal cancer (CRC)
surveillance
2O
ESMO GI 2025
COLORRECTAL
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse